ClinicalTrials.gg
WithdrawnNCT01303107Updated Mar 26, 2014

Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean

A Phase 3 interventional study of Bupivacaine in Cesarean Delivery, sponsored by Cristália Produtos Químicos Farmacêuticos Ltda.. Withdrawn at 2 sites in Brazil. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by Cristália Produtos Químicos Farmacêuticos Ltda. · Phase 3, Interventional, and Supportive care

Why this study was withdrawn
The Sponsor has no interest in continuing the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study is to determine if the mixture of enantiomers of bupivacaine (bupivacaine S75:R25) dos not represent inferiority efficacy and safety compare to the racemic mixture of enantiomers of bupivacaine (bupivacaine S50:R50).

Read the detailed description

The enantiomeric mixture of bupivacaine S75:R25 (75% levobupivacaine and 25% bupivacaine) was develop to be a safety regional anesthetic in substitution to racemic bupivacaine (S50:R50).

02

Conditions studied

  • Cesarean Delivery
03

In context

Lead sponsor

Cristália Produtos Químicos Farmacêuticos Ltda. is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • parturients at term
  • ASA () I or ASA II
  • elective cesarean section with low risk labor
  • pre-natal follow-up
  • patient consent

Exclusion criteria

Exclusion Criteria:

  • relative or absolute for spinal anesthesia
  • history of to the local anesthetics
  • use of opioids during labor
  • labor lasting more than 12 hours or less than 1 hour
  • complications of pregnancy such as placenta previa, pre-eclampsia or eclampsia; maternal-fetal malnutrition;important accidents during pregnancy.
  • spinal lesions, peripheral neuropathies or any other neurologic disorders that lead to changes of sensitivity and/or motricity
  • decompensated diabetes or hypertension
  • history of alcohol and/or drug abuse
  • cardiopathies, especially myocardiopathies and valvulopathies; important cognitive changes
  • changes in safety exams
  • twin pregnancy;
  • signs of intrauterine distress, and abnormalities of fetal vitality, prematurity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    bupivacaine S50:R50

    3 ml subarachnoid block

    Drug: Bupivacaine

  • Experimental
    bupivacaine S75:R25

    3 ml for subarachnoid block

    Drug: Bupivacaine

Interventions

  • single dose of 15 mg by a slow injection rate of 1 mL/s

    Also known as: Marcaine

06

What researchers measure

Primary outcomes

  1. latency of sensitive block at T6

    The anesthesiologist will evaluate the loss of pain to pin-prick in T10.

    Time frame: loss of pain in T6

Secondary outcomes

  1. duration of the anesthesia

    Time to recover the sensibility due to the anesthetic

    Time frame: recovery of the sensibility

  2. Degree of motor block

    Evaluated by the Bromage scale after the injection of the anesthetic solution

    Time frame: End of motor block

  3. maximal level of the sensitive blockade

    Evaluation by pin-prick every 2 minutes after the injection of the anesthetic solution.

    Time frame: last level of sensitive blockade

  4. Maternal cardiocirculatory and respiratory parameters

    systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) are evaluate during the study

    Time frame: During the study

  5. Parturients ambulation

    Will be measured the time that the parturients ambulate, due to de regression of the motor blockade

    Time frame: regression of the motor blockade

  6. Visceral pain

    Visceral pain will be assessed at the time of suture of the peritoneum.

    Time frame: suture of the peritoneum

  7. Neonatal repercussions

    Evaluation of the Apgar index in the first and fifth minutes.

    Time frame: birth of the neonatal

07

Study locations

2 sites
  • Irmandade da Santa Casa da Misericórdia de Santos
    Santos, São Paulo, Brazil
  • Irmandade da Santa Casa de Misericóridia de São Paulo
    São Paulo, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01303107
Lead sponsor
Cristália Produtos Químicos Farmacêuticos Ltda.
Collaborators
Irmandade da Santa Casa de Misericordia de Sao Paulo, Irmandade da Santa Casa da Misericórdia de Santos
Responsible party
Sponsor
First posted
Feb 24, 2011
Last update
Mar 26, 2014

Study contacts

Liga Mathias, PhD
principal investigator · Irmandade da Santa Casa de Misericórdia de São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion